Advanced Viral Research (ADVR) Announces Results of Topical Animal Study Indicating AVR 118 Accelerates Wound Healing.

YONKERS, N.Y. -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that a wound healing study topically applying its pharmaceutical drug AVR 118 to pigs has shown that AVR 118 accelerates the rate at which wounds heal. Although preliminary, these studies provide the rationale for advancing AVR 118 to the human testing stage.

"This study has already generated interest from two major dermatological and wound healing centers in North America and Europe and we intend to move forward with a clinical trial plan," says Stephen M. Elliston, President and CEO of Advanced Viral Research.

"These findings are extremely important because the regenerative properties of the pig model closely parallel those of humans. The wounds treated in this study with AVR 118 healed faster than those treated with a saline control" added Elliston.

Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.

Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.